Launched in May 2026 and founded by three pharmaceutical industry veterans, CELYSTRA Pharma acquires international therapeutic candidates and secures Canadian rights to commercialize them for underserved patient populations. Its first marketed product is olezarsen (TRYNGOLZA®), recently approved by Health Canada for familial chylomicronemia syndrome (FCS), a rare genetic disorder more prevalent in Québec. CELYSTRA also holds Canadian rights from Ionis Pharmaceuticals to donidalorsen, a therapy under regulatory review in Canada for hereditary angioedema (HAE). The company raised $20 million in a financing round that included Fonds de solidarité FTQ, the founders and other investors to support its launch and commercial activities. CELYSTRA positions itself to address unmet needs in rare and specialty diseases by bringing approved and late-stage international treatments to Canadian patients.

Total raised

$20M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2026